Because CD8+ T cells play essential roles against malignancy in immunotherapy, we further explored the impact of Liraglutide+αPD‐1 combination therapy on CD8+ T cells, enriching tumor‐infiltrated CD8+ T cells for further research. This evidence concerns the gene CD8A and neoplasm.